[1] Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood,2017,129(9):1095-1102.
[2] 王春红,金鑫,李景贺,等. 西达本胺治疗以RS3PE综合征为表现的血管免疫母细胞性T细胞淋巴瘤获部分缓解1例. 临床肿瘤学杂志,2018,23(01):89-92.
[3] 宋伟. 西达本胺联合依托泊苷、强的松、沙利度胺(CPET方案)治疗AITL患者的临床分析. 青岛大学,2019.
[4] 马军,石远凯,朱军,等. 西达本胺治疗外周T细胞淋巴瘤中国专家共识(2016版). 中国肿瘤临床,2016,43(08):317-323.
[5] Wang Y, Zhang M, Song W, et al. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. Am J Hematol,2022.
[6] 张立雄,朱润宇,魏长凤,等. 西达本胺的合成工艺研究. 中国药物化学杂志,2021,31(08):589-592.
[7] Yang D, Zhang WP, Yang JM, et al. Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report. Medicine (Baltimore),2018,97(49):e13093.
[8] 陈彦帆,韦燕,龚建忠,等. 恶性肿瘤化疗与乙肝病毒再激活及相关高危因素的临床分析. 实用癌症杂志,2012,27(01):45-47.
[9] 金世凯,孙立超. 乙型肝炎病毒表面抗原阴性伴核心抗体阳性非霍奇金淋巴瘤患者免疫化疗后肝炎病毒再激活的临床分析. 中国肿瘤临床与康复,2015,22(11):1318-1320.
[10] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology,2017,152(6):1297-1309.
[11] 王贵强,段钟平,王福生,等. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23(01):9-32.
[12] Aygen B, Demir AM, Gumus M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: consensus report. Turk J Gastroenterol,2018,29(3):259-269.
[13] Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol,2016,8(8):385-394. |
